Abstract: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide and
its prognosis remains poor. Molecular imaging with 18F-FDG PET/CT can metabolically characterize
the nature of lesions as benign or malignant, allowing a better staging at the diagnosis of this kind
of patient. This advantage can also be applied in the re-staging due to the suspicion of recurrent
disease. Many patients have a recurrence of the disease, including surgically treated patients. In the
current context, with new personalized oncological treatments, the surveillance for recurrence and
its accurate diagnosis are crucial to improve their survival. In this paper, we revise the current
knowledge about the clinical and molecular factors related to the recurrent disease. In the context
of new, promising, available personalized treatments, the role of molecular imaging with PET/CT
and 18F-FDG and non-18F-FDG radiotracers in the follow-up of NSCLC-treated patients is especially
attractive and interesting.
Otras publicaciones de la misma revista o congreso con autores/as de la Universidad de Cantabria
